Stockscreener 앱 받기
82.70
1.27%
1.04
전일 마감가:
$81.66
열려 있는:
$82.57
하루 거래량:
1.38M
Relative Volume:
0.78
시가총액:
$16.15B
수익:
$4.58B
순이익/손실:
$870.87M
주가수익비율:
18.80
EPS:
4.4
순현금흐름:
$945.58M
1주 성능:
-4.43%
1개월 성능:
-1.55%
6개월 성능:
+35.00%
1년 성능:
+26.98%
1일 변동 폭
$81.78
$82.95
1주일 범위
$81.09
$86.82
52주 변동 폭
$53.56
$87.99
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
82.70 | 15.95B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.74 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.90 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.40 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
711.62 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
326.06 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat
Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewswire Inc.
Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions - Yahoo Finance
Jim Cramer Calls Incyte “Way Too Cheap” - Yahoo Finance
Ruffer LLP Sells 9,988 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 24, 2025 - biospace.com
RBC Capital Raises Price Target for Incyte (INCY) to USD 81 | IN - GuruFocus
Incyte stock price target raised to $81 from $72 at RBC Capital - Investing.com
Guggenheim Reaffirms "Neutral" Rating for Incyte (NASDAQ:INCY) - MarketBeat
Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions - Insider Monkey
Mn Services Vermogensbeheer B.V. Sells 6,600 Shares of Incyte Corporation $INCY - MarketBeat
Is Incyte Stock Outperforming the S&P 500? - inkl
Incyte Corporation (NASDAQ:INCY) Short Interest Down 21.8% in August - MarketBeat
Incyte Corporation $INCY Stake Lowered by Diversified Trust Co - MarketBeat
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer - BioSpace
NorthCrest Asset Manangement LLC Has $777,000 Stock Holdings in Incyte Corporation $INCY - MarketBeat
Sovran Advisors LLC Sells 12,174 Shares of Incyte Corporation $INCY - MarketBeat
Incyte (NASDAQ:INCY) Price Target Raised to $115.00 at Stifel Nicolaus - MarketBeat
Stifel Raises Price Target for Incyte (INCY) to $115 While Maint - GuruFocus
Incyte appoints Dave Gardner as new chief strategy officer - Investing.com
Stifel Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
Incyte’s SWOT analysis: stock outlook mixed amid pipeline progress, jakafi concerns - Investing.com
Incyte stock price target raised to $115 by Stifel on pediatric approval - Investing.com
Incyte (NASDAQ:INCY) EVP Sells $23,115.70 in Stock - MarketBeat
Pallas Capital Advisors LLC Reduces Holdings in Incyte Corporation $INCY - MarketBeat
Perpetual Ltd Purchases New Holdings in Incyte Corporation $INCY - MarketBeat
34,082 Shares in Incyte Corporation $INCY Acquired by Strs Ohio - MarketBeat
How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval - Yahoo Finance
Swedbank AB Raises Stock Holdings in Incyte Corporation $INCY - MarketBeat
Baader Bank Aktiengesellschaft Invests $424,000 in Incyte Corporation $INCY - MarketBeat
4,558 Shares in Incyte Corporation $INCY Purchased by OMNI 360 Wealth Inc. - MarketBeat
Incyte Corporation (NASDAQ:INCY) Given Average Rating of "Hold" by Brokerages - MarketBeat
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
Guggenheim Reiterates Neutral Rating for Incyte (INCY) | INCY Stock News - GuruFocus
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - Yahoo Finance
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In ChildrenIncyte (NASDAQ:INCY) - Benzinga
Incyte (NASDAQ:INCY) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Invst LLC Makes New $315,000 Investment in Incyte Corporation $INCY - MarketBeat
Kera Capital Partners Inc. Invests $339,000 in Incyte Corporation $INCY - MarketBeat
CEO Change: Is Incyte Corporation showing insider buyingMarket Activity Summary & Advanced Technical Signal Analysis - خودرو بانک
Loss Report: What is the next catalyst for Incyte CorporationJuly 2025 Decliners & Target Return Focused Stock Picks - خودرو بانک
FDA approves Opzelura for atopic dermatitis in children ages 2 and up - Investing.com
US FDA approves Incyte's eczema cream for pediatric patients - Reuters
FDA Greenlights Incyte's Opzelura Cream for Pediatric Dermatitis Treatment - GuruFocus
FDA Approves Incyte's (INCY) Opzelura Cream for Pediatric Dermatitis - GuruFocus
Incyte gets FDA nod for Opzelura cream in atopic dermatitis treatment - Seeking Alpha
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis - Business Wire
Incyte stock rating reiterated by Citizens JMP amid promising drug data - Investing.com
Sivia Capital Partners LLC Purchases 7,206 Shares of Incyte Corporation $INCY - MarketBeat
Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT - Insider Monkey
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
인사이트 코퍼레이션 주식 (INCY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Sep 16 '25 |
Option Exercise |
64.25 |
278 |
17,862 |
33,478 |
| Denton Sheila A. | EVP & General Counsel |
Sep 16 '25 |
Sale |
83.15 |
278 |
23,116 |
33,200 |
3.41%
0.81%
자본화:
|
볼륨(24시간):